Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Announces $5 Million Milestone Payment from U.S. Commercial Sales of MONOVISC
Company Expects Total Revenue Growth of 23% to 26% for Q2 2017 BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced
View HTML
Toggle Summary Anika Announces Appointment of Joseph Darling as President
Track Record of Successful Product Launch and Global Commercial Expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Announces Appointment of Steven Chartier as Vice President of Regulatory and Clinical Affairs
Deep international expertise to drive the Company's global expansion BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today
View HTML
Toggle Summary Anika Announces Data Presentation and Symposium on CINGAL at 2017 EFORT Annual Congress
BEDFORD, Mass. & VIENNA --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to present Phase III data on CINGAL ® , its novel
View HTML
Toggle Summary Anika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society
-- Podium Sessions Showcase Studies Comparing HYALOFAST versus Collagen Scaffold and Microfracture Surgery for Cartilage Repair -- BEDFORD, Mass. & NAPLES, Italy --(BUSINESS WIRE)-- Anika Therapeutics, Inc. , ( NASDAQ : ANIK), a global, integrated orthopedics medicines company specializing in
View HTML
Toggle Summary Anika Announces European Commercial Launch of CINGAL for the Treatment of Pain Associated with Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. , ( NASDAQ : ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the commercial launch of CINGAL ® , its third-generation
View HTML
Toggle Summary Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from
View HTML
Toggle Summary Anika Announces First Patient Enrolled in Supplemental Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the enrollment of the first patient in its supplemental Phase III
View HTML
Toggle Summary Anika Announces Plans to Showcase HYALOFAST Hyaluronic Acid-Based Scaffold at the 2018 World Congress of the International Cartilage Repair Society
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced plans to showcase HYALOFAST ® , a biodegradable,
View HTML
Toggle Summary Anika Announces Publication of Data Demonstrating the Efficacy and Safety of HYALOFAST® in Combination with Stem Cells for the Treatment of Cartilage Lesions on the Knee
BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the publication of data demonstrating that HYALOFAST ® , a
View HTML